Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.31 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9400963 | 0.76 | TSHR (0.36) | TSHRHSD17B10TDP1 | |
| SCHEMBL16250 | 0.74 | TSHR (0.42) | TSHRSOAT1ALDH1A1 | |
| SCHEMBL386957 | 0.74 | NAAA (0.39) | TSHRALOX15SOAT1LMNANAAA | |
| Propionic Acid SCHEMBL29071063 | 0.74 | FFAR3 (0.56) | TSHRSOAT1LMNAALDH1A1HSD17B10 | |
| SCHEMBL1017110 | 0.74 | — | — | |
| SCHEMBL8840360 | 0.73 | ALDH1A1 (0.37) | TSHRALOX15SOAT1LMNAALDH1A1 | |
| SCHEMBL2138364 | 0.73 | SOAT1 (0.41) | TSHRALOX15SOAT1LMNAALDH1A1 | |
| SCHEMBL5706391 | 0.72 | ALDH1A1 (0.42) | TSHRALOX15SOAT1LMNANAAA | |
| SCHEMBL7709726 | 0.72 | — | — | |
| SCHEMBL5706390 | 0.72 | ALDH1A1 (0.42) | TSHRALOX15SOAT1LMNANAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981925-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056532-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | TSHR 4111/4885ALOX15 1014/4885SOAT1 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.